XENE
Xenon Pharmaceuticals Inc.
Price Chart
Latest Quote
$41.45
Current Price| Previous Close | $41.01 |
| Open | $41.01 |
| Day High | $42.13 |
| Day Low | $40.71 |
| Volume | 632,830 |
Stock Information
| Shares Outstanding | 77.28M |
| Total Debt | $8.33M |
| Cash Equivalents | $462.27M |
| Revenue | $7.50M |
| Net Income | $-306.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.20B |
| EPS (TTM) | $-3.89 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.01 |
| Debt to Earnings | -0.04 |
| Current Ratio | 17.85 |
| Quick Ratio | 17.66 |
| Avg Revenue Growth | -25.00% |
| Return on Equity | -31.04% |
| Avg FCF Growth | 39.45% |
| FCF Yield | -5.76% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $41.45 | 649,600 |
| 2026-01-30 | $41.01 | 631,700 |
| 2026-01-29 | $41.76 | 612,800 |
| 2026-01-28 | $41.95 | 610,300 |
| 2026-01-27 | $42.39 | 567,000 |
| 2026-01-26 | $42.20 | 1,161,400 |
| 2026-01-23 | $41.76 | 522,600 |
| 2026-01-22 | $42.24 | 1,283,000 |
| 2026-01-21 | $41.00 | 1,438,300 |
| 2026-01-20 | $41.49 | 738,800 |
| 2026-01-16 | $39.98 | 1,003,700 |
| 2026-01-15 | $40.74 | 865,700 |
| 2026-01-14 | $41.58 | 1,202,800 |
| 2026-01-13 | $40.36 | 698,900 |
| 2026-01-12 | $41.23 | 1,253,700 |
| 2026-01-09 | $42.15 | 2,055,700 |
| 2026-01-08 | $41.22 | 1,013,900 |
| 2026-01-07 | $42.12 | 1,300,100 |
| 2026-01-06 | $41.00 | 1,485,000 |
| 2026-01-05 | $41.79 | 1,526,100 |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
đ° Latest News
3 Biotech Stocks That Could Double In 2026
24/7 Wall St. âĸ 2026-01-20T15:42:47Z
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2026-01-17T12:24:05Z
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data?
Simply Wall St. âĸ 2025-12-08T00:08:08Z
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2025-12-04T16:30:21Z
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
Zacks âĸ 2025-12-03T16:30:18Z
Xenon Pharmaceuticals (XENE): Losses Widen 37% Annually, Challenging Bullish Revenue Growth Expectations
Simply Wall St. âĸ 2025-11-05T06:13:34Z
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Zacks âĸ 2025-11-04T14:54:00Z
Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlights: Strong Financial Position ...
GuruFocus.com âĸ 2025-11-04T05:01:18Z
Xenon Pharmaceuticals: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-03T21:32:56ZXenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum
Simply Wall St. âĸ 2025-10-12T10:09:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $9,434,000 | $18,437,000 |
| Operating Revenue | $0 | $0 | $9,434,000 | $18,437,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $279,298,000 | $214,054,000 | $138,577,000 | $97,430,000 |
| Other Income Expense | $-1,064,000 | $3,749,000 | $-4,825,000 | $-361,000 |
| Net Non Operating Interest Income Expense | $41,943,000 | $27,620,000 | $8,713,000 | $466,000 |
| Operating Expense | $279,298,000 | $214,054,000 | $138,577,000 | $97,430,000 |
| General And Administrative Expense | $68,904,000 | $46,542,000 | $32,810,000 | $21,967,000 |
| Interest Expense | - | - | $0 | $0 |
| Interest Expense Non Operating | - | - | $0 | $0 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-234,330,000 | $-182,393,000 | $-125,373,000 | $-78,882,000 |
| Net Interest Income | $41,943,000 | $27,620,000 | $8,713,000 | $466,000 |
| Interest Income | $41,943,000 | $27,620,000 | $8,713,000 | $466,000 |
| Normalized Income | $-233,284,088 | $-186,134,502 | $-121,812,632 | $-78,521,027 |
| Net Income From Continuing And Discontinued Operation | $-234,330,000 | $-182,393,000 | $-125,373,000 | $-78,882,000 |
| Total Operating Income As Reported | $-279,298,000 | $-214,054,000 | $-129,143,000 | $-78,993,000 |
| Net Income Common Stockholders | $-234,330,000 | $-182,393,000 | $-124,936,000 | $-77,087,000 |
| Net Income | $-234,330,000 | $-182,393,000 | $-125,373,000 | $-78,882,000 |
| Net Income Including Noncontrolling Interests | $-234,330,000 | $-182,393,000 | $-125,373,000 | $-78,882,000 |
| Net Income Continuous Operations | $-234,330,000 | $-182,393,000 | $-125,373,000 | $-78,882,000 |
| Pretax Income | $-238,419,000 | $-182,685,000 | $-125,255,000 | $-78,888,000 |
| Interest Income Non Operating | $41,943,000 | $27,620,000 | $8,713,000 | $466,000 |
| Operating Income | $-279,298,000 | $-214,054,000 | $-129,143,000 | $-78,993,000 |
| Special Income Charges | - | - | $0 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Basic EPS | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-18,088 | $7,498 | $-1,264,632 | $-27 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-275,674,000 | $-215,742,000 | $-122,913,000 | $-77,726,000 |
| Total Unusual Items | $-1,064,000 | $3,749,000 | $-4,825,000 | $-361,000 |
| Total Unusual Items Excluding Goodwill | $-1,064,000 | $3,749,000 | $-4,825,000 | $-361,000 |
| Reconciled Depreciation | $2,560,000 | $2,061,000 | $1,405,000 | $906,000 |
| EBITDA (Bullshit earnings) | $-276,738,000 | $-211,993,000 | $-127,738,000 | $-78,087,000 |
| EBIT | $-279,298,000 | $-214,054,000 | $-129,143,000 | $-78,993,000 |
| Diluted Average Shares | $77,894,643 | $66,889,005 | $60,542,142 | $43,627,452 |
| Basic Average Shares | $77,894,643 | $66,889,005 | $60,542,142 | $43,627,452 |
| Diluted NI Availto Com Stockholders | $-234,330,000 | $-182,393,000 | $-124,936,000 | $-77,087,000 |
| Tax Provision | $-4,089,000 | $-292,000 | $118,000 | $-6,000 |
| Gain On Sale Of Security | $-1,064,000 | $3,749,000 | $-4,825,000 | $-361,000 |
| Research And Development | $210,394,000 | $167,512,000 | $105,767,000 | $75,463,000 |
| Selling General And Administration | $68,904,000 | $46,542,000 | $32,810,000 | $21,967,000 |
| Other Gand A | $68,904,000 | $46,542,000 | $32,810,000 | $21,967,000 |
| Preferred Stock Dividends | - | - | $-437,000 | $-1,795,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $754,903,000 | $927,921,000 | $721,497,000 | $550,033,000 |
| Total Assets | $798,139,000 | $964,798,000 | $754,146,000 | $572,007,000 |
| Total Non Current Assets | $162,875,000 | $319,836,000 | $153,848,000 | $12,987,000 |
| Non Current Prepaid Assets | $7,496,000 | $7,396,000 | $7,751,000 | $0 |
| Non Current Deferred Assets | $9,666,000 | $802,000 | $509,000 | $465,000 |
| Non Current Deferred Taxes Assets | $9,666,000 | $802,000 | $509,000 | $465,000 |
| Investmentin Financial Assets | $127,496,000 | $292,792,000 | $128,682,000 | $0 |
| Current Assets | $635,264,000 | $644,962,000 | $600,298,000 | $559,020,000 |
| Other Current Assets | $6,890,000 | $6,006,000 | $7,225,000 | $4,481,000 |
| Receivables | $1,469,000 | $874,000 | $986,000 | $2,765,000 |
| Accounts Receivable | $1,469,000 | $874,000 | $986,000 | $2,765,000 |
| Cash Cash Equivalents And Short Term Investments | $626,905,000 | $638,082,000 | $592,087,000 | $551,774,000 |
| Cash And Cash Equivalents | $142,712,000 | $148,643,000 | $57,242,000 | $175,688,000 |
| Prepaid Assets | - | - | - | $4,481,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $9,015,000 | $10,903,000 | $10,435,000 | $8,257,000 |
| Long Term Debt And Capital Lease Obligation | $7,646,000 | $9,604,000 | $9,947,000 | $7,652,000 |
| Current Debt And Capital Lease Obligation | $1,369,000 | $1,299,000 | $488,000 | $605,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $43,236,000 | $36,877,000 | $32,649,000 | $21,974,000 |
| Total Non Current Liabilities Net Minority Interest | $7,646,000 | $9,604,000 | $9,947,000 | $7,652,000 |
| Current Liabilities | $35,590,000 | $27,273,000 | $22,702,000 | $14,322,000 |
| Payables And Accrued Expenses | $24,293,000 | $18,549,000 | $16,391,000 | $7,777,000 |
| Payables | $10,756,000 | $8,945,000 | $8,491,000 | $3,824,000 |
| Total Tax Payable | $5,686,000 | $347,000 | - | - |
| Accounts Payable | $5,070,000 | $8,598,000 | $8,491,000 | $3,824,000 |
| Current Deferred Liabilities | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $754,903,000 | $927,921,000 | $721,497,000 | $542,301,000 |
| Total Equity Gross Minority Interest | $754,903,000 | $927,921,000 | $721,497,000 | $550,033,000 |
| Stockholders Equity | $754,903,000 | $927,921,000 | $721,497,000 | $550,033,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,612,000 | $-77,000 | $-3,000,000 | $-990,000 |
| Other Equity Adjustments | $-1,612,000 | $-77,000 | $-3,000,000 | $-990,000 |
| Retained Earnings | $-899,470,000 | $-665,140,000 | $-482,747,000 | $-357,374,000 |
| Preferred Stock Equity | - | - | - | $7,732,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $76,416,086 | $75,370,977 | $62,587,701 | $51,634,752 |
| Share Issued | $76,416,086 | $75,370,977 | $62,587,701 | $51,634,752 |
| Tangible Book Value | $754,903,000 | $927,921,000 | $721,497,000 | $542,301,000 |
| Invested Capital | $754,903,000 | $927,921,000 | $721,497,000 | $542,301,000 |
| Working Capital | $599,674,000 | $617,689,000 | $577,596,000 | $544,698,000 |
| Capital Lease Obligations | $9,015,000 | $10,903,000 | $10,435,000 | $8,257,000 |
| Total Capitalization | $754,903,000 | $927,921,000 | $721,497,000 | $550,033,000 |
| Additional Paid In Capital | $199,149,000 | $156,764,000 | $142,108,000 | $117,495,000 |
| Capital Stock | $1,456,836,000 | $1,436,374,000 | $1,065,136,000 | $790,902,000 |
| Common Stock | $1,456,836,000 | $1,436,374,000 | $1,065,136,000 | $783,170,000 |
| Long Term Capital Lease Obligation | $7,646,000 | $9,604,000 | $9,947,000 | $7,652,000 |
| Current Capital Lease Obligation | $1,369,000 | $1,299,000 | $488,000 | $605,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,928,000 | $7,425,000 | $5,823,000 | $5,940,000 |
| Current Accrued Expenses | $13,537,000 | $9,604,000 | $7,900,000 | $3,953,000 |
| Investments And Advances | $127,496,000 | $292,792,000 | $128,682,000 | $0 |
| Available For Sale Securities | $127,496,000 | $292,792,000 | $128,682,000 | - |
| Net PPE | $18,217,000 | $18,846,000 | $16,906,000 | $12,522,000 |
| Accumulated Depreciation | $-13,464,000 | $-11,251,000 | $-8,705,000 | $-13,350,000 |
| Gross PPE | $31,681,000 | $30,097,000 | $25,611,000 | $25,872,000 |
| Leases | $9,363,000 | $9,019,000 | $4,203,000 | $7,021,000 |
| Other Properties | $11,631,000 | $9,111,000 | $8,921,000 | $8,424,000 |
| Machinery Furniture Equipment | $2,748,000 | $2,774,000 | $2,081,000 | $2,371,000 |
| Buildings And Improvements | $7,939,000 | $9,193,000 | $10,406,000 | $8,056,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $484,193,000 | $489,439,000 | $534,845,000 | $376,086,000 |
| Treasury Shares Number | - | $0 | - | - |
| Preferred Stock | - | - | $0 | $7,732,000 |
| Current Deferred Revenue | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-184,464,000 | $-156,729,000 | $-103,922,000 | $-71,552,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-181,389,000 | $-151,112,000 | $-101,028,000 | $-69,502,000 |
| Cash Flow From Continuing Operating Activities | $-181,389,000 | $-151,112,000 | $-101,028,000 | $-69,502,000 |
| Operating Gains Losses | $745,000 | $-640,000 | $2,729,000 | $327,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-3,075,000 | $-5,617,000 | $-2,894,000 | $-2,050,000 |
| Investing Cash Flow | $165,000,000 | $-111,385,000 | $-293,405,000 | $-246,770,000 |
| Cash Flow From Continuing Investing Activities | $165,000,000 | $-111,385,000 | $-293,405,000 | $-246,770,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $12,083,000 | $353,487,000 | $277,766,000 | $447,283,000 |
| Financing Cash Flow | $12,130,000 | $353,522,000 | $278,471,000 | $447,543,000 |
| Cash Flow From Continuing Financing Activities | $12,130,000 | $353,522,000 | $278,471,000 | $447,543,000 |
| Net Common Stock Issuance | $12,083,000 | $353,487,000 | $277,766,000 | $447,283,000 |
| Common Stock Issuance | $12,083,000 | $353,487,000 | $277,766,000 | $447,283,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $142,712,000 | $148,643,000 | $57,242,000 | $175,688,000 |
| Beginning Cash Position | $148,643,000 | $57,242,000 | $175,688,000 | $45,009,000 |
| Effect Of Exchange Rate Changes | $-1,672,000 | $376,000 | $-2,484,000 | $-592,000 |
| Changes In Cash | $-4,259,000 | $91,025,000 | $-115,962,000 | $131,271,000 |
| Proceeds From Stock Option Exercised | $47,000 | $35,000 | $705,000 | $260,000 |
| Net Investment Purchase And Sale | $168,075,000 | $-105,768,000 | $-290,511,000 | $-244,720,000 |
| Sale Of Investment | $700,343,000 | $688,139,000 | $260,626,000 | $144,754,000 |
| Purchase Of Investment | $-532,268,000 | $-793,907,000 | $-551,137,000 | $-389,474,000 |
| Net PPE Purchase And Sale | $-3,075,000 | $-5,617,000 | $-2,894,000 | $-2,050,000 |
| Purchase Of PPE | $-3,075,000 | $-5,617,000 | $-2,894,000 | $-2,050,000 |
| Change In Working Capital | $5,713,000 | $5,902,000 | $-1,276,000 | $-2,647,000 |
| Change In Other Current Liabilities | $-1,220,000 | $267,000 | $-600,000 | - |
| Change In Payables And Accrued Expense | $8,531,000 | $3,931,000 | $8,062,000 | $2,971,000 |
| Change In Prepaid Assets | $-984,000 | $1,574,000 | $-10,495,000 | $-1,517,000 |
| Change In Receivables | $-614,000 | $130,000 | $1,757,000 | $-459,000 |
| Changes In Account Receivables | $-614,000 | $130,000 | $1,757,000 | $-459,000 |
| Other Non Cash Items | $1,254,000 | $1,213,000 | $819,000 | - |
| Stock Based Compensation | $50,717,000 | $32,372,000 | $20,376,000 | $10,017,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $-3,550,000 | $2,934,000 | $719,000 |
| Amortization Of Securities | $816,000 | $-5,785,000 | $-2,598,000 | - |
| Deferred Tax | $-8,864,000 | $-292,000 | $-44,000 | $58,000 |
| Deferred Income Tax | $-8,864,000 | $-292,000 | $-44,000 | $58,000 |
| Depreciation Amortization Depletion | $2,560,000 | $2,061,000 | $1,405,000 | $906,000 |
| Depreciation And Amortization | $2,560,000 | $2,061,000 | $1,405,000 | $906,000 |
| Depreciation | $2,560,000 | $2,061,000 | $1,405,000 | $906,000 |
| Net Foreign Currency Exchange Gain Loss | $745,000 | $-640,000 | $2,729,000 | $327,000 |
| Net Income From Continuing Operations | $-234,330,000 | $-182,393,000 | $-125,373,000 | $-78,882,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | $2,934,000 | $719,000 |
| Change In Other Working Capital | - | - | - | $-3,642,000 |